{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T15:42:55Z","timestamp":1724427775319},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2013,10,29]],"date-time":"2013-10-29T00:00:00Z","timestamp":1383004800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0077530","type":"journal-article","created":{"date-parts":[[2013,10,29]],"date-time":"2013-10-29T22:55:23Z","timestamp":1383087323000},"page":"e77530","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Association of IFNL3 rs12979860 and rs8099917 with Biochemical Predictors of Interferon Responsiveness in Chronic Hepatitis C Virus Infection"],"prefix":"10.1371","volume":"8","author":[{"given":"Janett","family":"Fischer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiko","family":"Witt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Sarrazin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Susser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Migaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eckart","family":"Schott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Brodzinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balazs","family":"F\u00fcl\u00f6p","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"van B\u00f6mmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,10,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"(4)","author":"JF Perz","year":"2006","journal-title":"J Hepatol 45"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/hep.25647","article-title":"Dysregulation of innate immunity in HCV genotype 1 IL28B unfavorable genotype patients: Impaired viral kinetics and therapeutic response","volume":"54(2)","author":"S Naggie","year":"2012","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-230X-12-71","article-title":"Extent of liver inflammation in predicting response to interferon alpha &amp; Ribavirin in chronic hepatitis C patients: a cohort study","volume":"(1)","author":"S Mirza","year":"2012","journal-title":"BMC Gastroenterol 12"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Petta S, Ferraro D, Camma C, Cabibi D, Di Cristina A, <etal>et al<\/etal>.. (2012) Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Antivir Ther (17(5): 823\u201331).","DOI":"10.3851\/IMP2100"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00535-011-0458-y","article-title":"The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection","volume":"(12)","author":"V Weich","year":"2011","journal-title":"J Gastroenterol 46"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/hep.22991","article-title":"Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1\u2013infected patients","volume":"(2)","author":"T Berg","year":"2009","journal-title":"Hepatology 50"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1053\/jhep.2003.50106","article-title":"Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy","volume":"(3)","author":"T Berg","year":"2003","journal-title":"Hepatology 37"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/hep.26203","article-title":"Association of \u03b3-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV)","volume":"(5)","author":"JE Everhart","year":"2013","journal-title":"Hepatology 57"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"(9286)","author":"MP Manns","year":"2001","journal-title":"The Lancet 358"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1440-1746.2011.06834.x","article-title":"Predicting response to therapy in chronic hepatitis C: An approach combining interleukin-28B gene polymorphisms and clinical data","volume":"(2)","author":"JM Ladero","year":"2012","journal-title":"J Gastroenterol Hepatol 27"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/hep.23787","article-title":"Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy","volume":"(3)","author":"SA Harrison","year":"2010","journal-title":"Hepatology 52"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"(7262)","author":"D Ge","year":"2009","journal-title":"Nature 461"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-[alpha] and ribavirin therapy","volume":"(10)","author":"V Suppiah","year":"2009","journal-title":"Nat Genet 41"},{"key":"ref14","first-page":"1105","article-title":"Genome-wide association of IL28B with response to pegylated interferon-[alpha] and ribavirin therapy for chronic hepatitis C. Nat Genet 41","volume":"(10)","author":"Y Tanaka","year":"2009"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study","volume":"(4)","author":"A Rauch","year":"2010","journal-title":"Gastroenterology 138"},{"key":"ref16","first-page":"499","article-title":"Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139","volume":"(2)","author":"M Honda","year":"2010"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"(7265)","author":"DL Thomas","year":"2009","journal-title":"Nature 461"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2217\/pgs.09.121","article-title":"Host genetic determinants of spontaneous hepatitis C clearance","volume":"(11)","author":"A Rauch","year":"2009","journal-title":"Pharmacogenomics 10"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1053\/j.gastro.2010.07.005","article-title":"A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice","volume":"(5)","author":"HL Tillmann","year":"2010","journal-title":"Gastroenterology 139"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/hep.25792","article-title":"Will IL28B polymorphism remain relevant in the era of direct acting antiviral agents for HCV","volume":"(1)","author":"AJ Thompson","year":"2012","journal-title":"Hepatology 56"},{"key":"ref21","first-page":"344","article-title":"Impact of IL28B genotype on the early and sustained virologic response in treatment-na\u00efve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 9","volume":"(4)","author":"AF St\u00e4ttermayer","year":"2011"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1159\/000323526","article-title":"Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment","volume":"(6)","author":"N Akuta","year":"2012","journal-title":"Intervirology 55"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1478-3231.2011.02718.x","article-title":"Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir","volume":"32","author":"ML Shiffman","year":"2012","journal-title":"Liver Int"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jmv.22158","article-title":"Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state","volume":"(9)","author":"H Abe","year":"2011","journal-title":"J Med Virol 83"},{"key":"ref25","first-page":"7034","article-title":"Interferon signaling and treatment outcome in chronic hepatitis C. PNAS 105","volume":"(19)","author":"M Sarasin-Filipowicz","year":"2008"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.24623","article-title":"Association of gene expression involving innate immunity and genetic variation in IL28B with antiviral response","volume":"(1)","author":"Y Asahina","year":"2012","journal-title":"Hepatology 55"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/hep.21853","article-title":"Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response","volume":"(5)","author":"JJ Feld","year":"2007","journal-title":"Hepatology 46"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2005.01.059","article-title":"Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection","volume":"(5)","author":"L Chen","year":"2005","journal-title":"Gastroenterology 128"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000339879","article-title":"High predictability of a sustained virological response (87%) in chronic hepatitis C virus genotype 1 infection treatment by combined IL28B genotype analysis and \u03b3-glutamyltransferase\/alanine aminotransferase ratio: a retrospective single-center study","volume":"(3)","author":"A Amanzada","year":"2012","journal-title":"Digestion 86"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"(2)","author":"L Prokunina-Olsson","year":"2013","journal-title":"Nat Genet 45"},{"key":"ref31","first-page":"119","article-title":"Loss of function of the new interferon IFN-[lambda]4 may confer protection from hepatitis C. Nat Genet 45","volume":"(2)","author":"D Booth","year":"2013"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.26443","article-title":"Interferon-lambda polymorphisms and hepatitis C virus clearance revisited","volume":"(1)","author":"J Lupberger","year":"2013","journal-title":"Hepatology 58"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1053\/j.gastro.2011.07.019","article-title":"Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24\u201372 weeks","volume":"(5)","author":"C Sarrazin","year":"2011","journal-title":"Gastroenterology 141"},{"key":"ref34","first-page":"518","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38","volume":"(2)","author":"C Wai","year":"2003"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/hep.1840190629","article-title":"Classification of chronic hepatitis: Diagnosis, grading and staging","volume":"(6)","author":"VJ Desmet","year":"1994","journal-title":"Hepatology 19"},{"key":"ref36","first-page":"289","article-title":"An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24","volume":"(2)","author":"P Bedossa","year":"1996"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/hep.25582","article-title":"Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection","volume":"(6)","author":"J Fischer","year":"2012","journal-title":"Hepatology 55"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"(1)","author":"WJ Youden","year":"1950","journal-title":"Cancer 3"},{"key":"ref39","first-page":"527","article-title":"IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 56","volume":"(3)","author":"T Asselah","year":"2012"},{"key":"ref40","first-page":"w13586","article-title":"Interferons and hepatitis C virus","volume":"142","author":"MH Heim","year":"2012","journal-title":"Swiss Med Wkly"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0021-9258(17)42492-6","article-title":"Transcriptional induction by interferon. New protein(s) determine the extent and length of the induction","volume":"(1)","author":"AC Larner","year":"1986","journal-title":"J Biol Chem 261"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1128\/MCB.00224-09","article-title":"Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18\/UBP43","volume":"(17)","author":"M Sarasin-Filipowicz","year":"2009","journal-title":"Mol Cell Bio 29"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1365-2893.2005.00655.x","article-title":"Serum lipid pattern in chronic hepatitis C: histological and virological correlations","volume":"(1)","author":"D Siagris","year":"2006","journal-title":"J Viral Hepat 13"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.jhep.2012.01.007","article-title":"IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease","volume":"(6)","author":"S Petta","year":"2012","journal-title":"J Hepatol 56"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/jmv.23259","article-title":"The interleukin 28B rs12979860 C\/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases","volume":"(5)","author":"C Fabris","year":"2012","journal-title":"J Med Virol 84"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.ATV.12.9.1053","article-title":"The effect of interferon on the metabolism of LDLs","volume":"(9)","author":"G Schectman","year":"1992","journal-title":"Arterioscler Thromb 12"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cyto.2010.03.004","article-title":"IFN-\u03bb endocytosis and IFN-\u03bb responsive promoter activation are dependent on cholesterol","volume":"(1)","author":"O Cho","year":"2010","journal-title":"Cytokine 51"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Berg T, Andreone P, Pol S, Roberts SK, Younossi ZM, <etal>et al<\/etal>.. (2011) Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon\/ribavirin treatment failure post-hoc analysis of the phase III REALIZE study. Hepatology 54 (4 Suppl): 375A.","DOI":"10.1016\/S1590-8658(12)60066-8"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.clinre.2012.07.002","article-title":"Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs)","volume":"(1)","author":"DA Sheridan","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol 37"},{"key":"ref50","first-page":"1","article-title":"A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 19","volume":"(S1)","author":"IM Jacobson","year":"2012"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Sulkowski MS, Asselah T, Ferenci P, Stern JO, Kukolj G, <etal>et al<\/etal>.. (2011) Treatment with the second generation HCV protease inhibitor BI201335 results in high and consistent SVR rates \u2013 results from SILEN-C1 in treatment-naive patients across different baseline factors. Hepatology 54(4 Suppl): 473A.","DOI":"10.1016\/S0168-8278(11)60062-7"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1084\/jem.20130012","article-title":"IL28B expression depends on a novel TT\/\u2212G polymorphism which improves HCV clearance prediction","volume":"(6)","author":"S Bibert","year":"2013","journal-title":"J Exp Med 210"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0077530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T22:27:12Z","timestamp":1646951232000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0077530"}},"subtitle":[],"editor":[{"given":"David Richmond","family":"Booth","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,10,29]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,10,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0077530","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,29]]}}}